Outpace Bio ends cell therapy trial: The Seattle startup canned a Phase 1 …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Aspen and Bambusa target $135M IPOs; AstraZeneca vs. Takeda in gastric cancer ADCs October 26, 2026
A hepatitis B hold lifted and drug tabled; Ultomiris' accelerated approval October 22, 2026
Post-Makary FDA wins over investors, but not scientists or Big Pharma: Signal Survey
Artiva to wind down after two patient deaths in autoimmune cell therapy trials
Source link







